JP4450505B2 - 志賀毒素誘発性疾患を防御するヒト化モノクローナル抗体 - Google Patents

志賀毒素誘発性疾患を防御するヒト化モノクローナル抗体 Download PDF

Info

Publication number
JP4450505B2
JP4450505B2 JP2000525563A JP2000525563A JP4450505B2 JP 4450505 B2 JP4450505 B2 JP 4450505B2 JP 2000525563 A JP2000525563 A JP 2000525563A JP 2000525563 A JP2000525563 A JP 2000525563A JP 4450505 B2 JP4450505 B2 JP 4450505B2
Authority
JP
Japan
Prior art keywords
antibody
variable region
constant region
human
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000525563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003521219A (ja
JP2003521219A5 (https=
Inventor
スティンソン，ジェフリー，アール．
ウォン，ヒング
オブライエン，アリソン，ディー．
シュミット，クレア，ケー．
メルトン−セルサ，アンジェラ
Original Assignee
ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン
サンオール モレキュラー コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン, サンオール モレキュラー コーポレーション filed Critical ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン
Publication of JP2003521219A publication Critical patent/JP2003521219A/ja
Publication of JP2003521219A5 publication Critical patent/JP2003521219A5/ja
Application granted granted Critical
Publication of JP4450505B2 publication Critical patent/JP4450505B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000525563A 1997-12-23 1998-12-22 志賀毒素誘発性疾患を防御するヒト化モノクローナル抗体 Expired - Fee Related JP4450505B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6863597P 1997-12-23 1997-12-23
US60/068,635 1997-12-23
US09/215,163 1998-12-18
US09/215,163 US20030170248A1 (en) 1997-12-23 1998-12-18 Humanized monoclonal antibodies that protect against shiga toxin induced disease
PCT/US1998/027267 WO1999032645A1 (en) 1997-12-23 1998-12-22 Humanized monoclonal antibodies that protect against shiga toxin induced disease

Publications (3)

Publication Number Publication Date
JP2003521219A JP2003521219A (ja) 2003-07-15
JP2003521219A5 JP2003521219A5 (https=) 2006-01-05
JP4450505B2 true JP4450505B2 (ja) 2010-04-14

Family

ID=26749187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000525563A Expired - Fee Related JP4450505B2 (ja) 1997-12-23 1998-12-22 志賀毒素誘発性疾患を防御するヒト化モノクローナル抗体

Country Status (11)

Country Link
US (6) US20030170248A1 (https=)
EP (1) EP1042492B1 (https=)
JP (1) JP4450505B2 (https=)
AT (1) ATE449856T1 (https=)
AU (1) AU764091B2 (https=)
CA (1) CA2316411C (https=)
DE (1) DE69841331D1 (https=)
DK (1) DK1042492T3 (https=)
ES (1) ES2339618T3 (https=)
PT (1) PT1042492E (https=)
WO (1) WO1999032645A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
DK1079856T3 (da) * 1998-05-20 2006-12-04 Teijin Ltd Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CN100523216C (zh) * 2001-03-02 2009-08-05 匹兹堡大学 Pcr方法
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
CN100441689C (zh) * 2006-01-20 2008-12-10 中国人民解放军第三军医大学 抗ehec o157志贺样毒素ⅱa亚单位单克隆抗体5f3轻、重链可变区基因及应用
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
CA2652999A1 (en) * 2006-05-31 2007-12-13 Thallion Pharmaceuticals Incorporated Methods, compositions, and kits for treating shiga toxin associated conditions
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
EP2172481B1 (en) * 2008-10-06 2014-10-29 Novoplant GmbH Proteolytically stable antibody formats
KR101832499B1 (ko) * 2009-01-23 2018-02-26 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 시가 독소 2형 단백질 기반 방법 및 조성물
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5164298A (en) * 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5747272A (en) * 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
US5968894A (en) * 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
US7910096B2 (en) * 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
US20020160005A1 (en) * 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
WO1998020903A1 (en) 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
ATE504312T1 (de) * 2003-07-21 2011-04-15 Intervet Int Bv Hybrid-toxine mit shiga-artigen toxin- untereinheiten, verbunden mit escherichia coli wärmeinstabilen enterotoxin-untereinheiten und vakzine daraus
CA2555306A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
JP5409014B2 (ja) * 2006-02-16 2014-02-05 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 志賀トキソイドキメラタンパク質
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions

Also Published As

Publication number Publication date
CA2316411C (en) 2009-02-17
US20100166753A1 (en) 2010-07-01
PT1042492E (pt) 2010-01-08
US20140135481A1 (en) 2014-05-15
EP1042492A1 (en) 2000-10-11
WO1999032645A1 (en) 1999-07-01
EP1042492B1 (en) 2009-11-25
DK1042492T3 (da) 2010-01-18
US20070003560A1 (en) 2007-01-04
JP2003521219A (ja) 2003-07-15
AU2090299A (en) 1999-07-12
AU764091B2 (en) 2003-08-07
ATE449856T1 (de) 2009-12-15
DE69841331D1 (de) 2010-01-07
US20070160607A1 (en) 2007-07-12
US20030170248A1 (en) 2003-09-11
CA2316411A1 (en) 1999-07-01
ES2339618T3 (es) 2010-05-21
US20100189715A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
US20100166753A1 (en) Humanized monoclonal antibodies that protect against shiga toxin induced disease
ES2363689T3 (es) Anticuerpos monoclonales y quiméricos, opsónicos y protectores, específicos para el ácido lipoteicoico de bacterías gram positivas.
US7777017B2 (en) Nucleic acids encoding opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
EP2134749B1 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20110171235A1 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AU2009202762B2 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
AU2018202199A1 (en) Clostridium difficile antibodies
JP2010013454A (ja) グラム陽性細菌のペプチドグリカンに対する多機能性モノクローナル抗体
KR20120128687A (ko) 녹농균의 혈청형 ｇ 지질다당류에 대한 항체
AU2013251165A1 (en) Cross-reactive Staphylococcus aureus antibody
JP2001500730A (ja) ヒスチジン―タグ付き志賀毒素およびトキソイド、該毒素およびトキソイドとの融合タンパク質ならびにそれらの精製及び調製方法
US20080014202A1 (en) Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
CN120943954B (zh) 抗金黄色葡萄球菌IsdB抗体的制备及其应用
JP2005514053A6 (ja) グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体
WO2014160098A2 (en) Bordetella specific human recombinant antibodies and uses thereof
US20220080036A1 (en) Human monoclonal antibodies to staphylococcal aureus isd proteins and uses thereof
Motley The Role of Anti-Capsular Antibodies in Protection Against Carbapenem-Resistant Klebsiella Pneumoniae
Baranova Adaptation of Vibrio cholerae O1 to Protective, Lipopolysaccharide-Specific Antibodies in the Intestinal Lumen
AU2012254925B2 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
Almdni Recombinant antibodies against Clostridium difficile toxin A
Severson Bacterial stimulation of gut-associated lymphoid tissue development

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080627

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100105

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100126

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130205

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140205

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees